DILI Associated With Tocilizumab in a Patient With COVID-19 DILI Associated With Tocilizumab in a Patient With COVID-19

This case report warns of a rare but potentially serious hepatotoxicity associated with the IL-6 receptor antagonist tocilizumab, administered to a patient with COVID-19 to treat cytokine storm.Liver International

Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news